Ipamorelin is a lab-made five-amino-acid peptide that mimics ghrelin, a hormone that stimulates growth hormone release. It was first synthesized by Novo Nordisk researchers in the mid-1990s.3 It is not an FDA-approved drug. FDA’s 2024 evaluation found that neither ipamorelin nor ipamorelin acetate is a component of an FDA-approved drug.3 Its main human study, a small randomized trial after bowel surgery, did not show a statistically significant benefit, and FDA concluded the evidence for growth hormone deficiency or recovery after surgery is limited.3 FDA staff recommended against adding ipamorelin to the list of substances pharmacies may use in compounding, and ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,6
Ipamorelin at a glance
What it is
A synthetic peptide of five amino acids, including unnatural ones, that acts as a ghrelin mimetic and stimulates growth hormone release.3
FDA status
Not FDA-approved. FDA staff recommended in 2024 against adding either form to the 503A compounding list, and FDA lists ipamorelin acetate among compounding substances that may present significant safety risks under its 503B interim policy.1,3
Human evidence
One small randomized, placebo-controlled trial after bowel surgery that found no statistically significant benefit, and a placebo-controlled pharmacology study in 48 healthy men.3
Sport status
FDA’s 2024 briefing notes that ipamorelin is on the World Anti-Doping Agency’s prohibited list under section S2.4.3
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide, a chain of five amino acids that includes unnatural amino acids. FDA describes it as a ghrelin mimetic, meaning it imitates ghrelin, a hormone that stimulates growth hormone release.3
FDA’s briefing states that Novo Nordisk researchers first synthesized it in the mid-1990s and that it was first described in the literature in 1998. It exists as a free base and as an acetate salt, which FDA treats as different substances.3
FDA found it marketed by wellness clinics and medical spas for uses such as weight loss, anti-aging, sleep and bodybuilding, sometimes combined with other peptides such as sermorelin. Outsourcing facilities reported compounding it from 2017 to 2020.3
How is ipamorelin thought to work?
FDA’s briefing describes ipamorelin as acting mainly through ghrelin receptors in the brain and on pituitary cells to stimulate growth hormone release.3
FDA notes that peptides with unnatural amino acids are harder to characterize, and that impurities or clumping of peptide chains could make immune reactions more likely.3
What do human studies show?
FDA found one clinical study of ipamorelin’s effectiveness: a Phase 2, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults having bowel surgery, published in 2014, in which 114 received ipamorelin or placebo.3
The median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a difference the study reported as not statistically significant. Secondary measures of bowel recovery and hospital stay also showed no differences.3
FDA notes that adverse events in that trial included low potassium, insomnia, high blood sugar, nausea, vomiting, abdominal swelling and two deaths, and that it is unclear whether the deaths were related to ipamorelin. FDA cites a later report that development for this use was discontinued.3
The study cited to FDA for growth hormone deficiency was a randomized, placebo-controlled pharmacology study in 48 healthy men that reported no effectiveness data. FDA found no other publications evaluating ipamorelin for growth hormone deficiency.3
What the evidence base contains
Controlled human trial A Phase 2, multicenter, randomized, double-blind, placebo-controlled trial in 117 hospitalized adults after bowel resection, of whom 114 received study drug, published in 2014. FDA reports that its main result was not statistically significant.3
Controlled human trial A randomized, placebo-controlled pharmacology study in 48 healthy men that measured blood levels and growth hormone responses. FDA notes it reported no effectiveness data.3
No. FDA’s evaluation, dated August 19, 2024, states that neither ipamorelin (free base) nor ipamorelin acetate is a component of an FDA-approved drug, and that there is no United States Pharmacopeia monograph for either.3
FDA staff evaluated both forms for the 503A bulks list, the list of substances that pharmacies may use in compounding, for growth hormone deficiency and recovery of bowel function after surgery. They concluded that the balance of criteria weighs against adding either form, citing poor characterization data, limited evidence of effectiveness and safety concerns.3
A Federal Register notice announced that FDA’s Pharmacy Compounding Advisory Committee would discuss ipamorelin-related substances at its October 29, 2024 meeting. FDA’s briefing states that FDA will not issue a final determination until the committee’s input has been considered and all reviews are finalized.3,4
FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.1
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Ipamorelin is not among them.5,6
FDA’s briefing also notes that Australia’s medicines scheduling committee added ipamorelin to its Poisons Standard as a performance and image enhancing drug. None of the sources reviewed here reports an approval of ipamorelin in any country.3
Timeline
Ipamorelin is first described in the scientific literature, according to FDA’s briefing.3
Ipamorelin acetate is placed in category 2 under FDA’s 503B interim policy, according to FDA’s compounding safety-risk page.1
FDA staff date their evaluation recommending against adding ipamorelin to the 503A bulks list.3
A Federal Register notice announces the October 29, 2024 advisory-committee meeting that will discuss ipamorelin.4
FDA’s Pharmacy Compounding Advisory Committee meets to discuss ipamorelin-related substances.3,4
FDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.1
What is still unknown?
Whether ipamorelin has any clinical benefit: FDA found the evidence for growth hormone deficiency and recovery after surgery limited.3
Its safety in the compounded form that was nominated, for which FDA says there are no safety data.3
What is in products sold under the name: FDA notes that the free base and acetate forms are different substances and that the nominations did not make clear which one was proposed.3
FDA’s final decision on the 503A list, which was not part of the sources reviewed through November 14, 2026.1,3
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Ipamorelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Ipamorelin are the records PeptideScanner has selected and published, not every registration or paper about Ipamorelin. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.↗↗↗↗
What the reviewed sources report
The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit. The additional urine studies concern detection and receptor binding, not therapeutic benefit.↗↗↗↗
What remains unresolved?
Are there adequately controlled studies for proposed uses outside postoperative bowel recovery?↗↗
How do route, formulation and follow-up affect what can be concluded about harms?↗↗
FDA assessment dated August 19, 2024 · Read September 15, 2026 · Preserved version 1
FDA's evaluation of ipamorelin free base and acetate for growth hormone deficiency and postoperative ileus, prepared for the October 2024 advisory meeting. It is a dated agency assessment, not a final compounding determination. FDA document ↗
Identity and approval scope
FDA distinguishes free base from acetate and states that neither was a component of an FDA-approved drug at the time of its assessment. Study reports did not always identify the form administered. FDA pp. 6, 35 ↗
What did FDA find about effectiveness?
FDA found insufficient evidence supporting the evaluated uses and no clinical effectiveness or safety data for the proposed subcutaneous route. Intravenous postoperative findings do not establish subcutaneous effectiveness. FDA pp. 42, 43 ↗
Serious events require explicit context
FDA reports two deaths among ipamorelin-treated postoperative patients, alongside higher rates of hypokalemia and hyperglycemia. The agency explicitly states that whether the deaths were related to ipamorelin is unclear. FDA pp. 37, 42 ↗
Scope, source pin and remaining work
This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.
Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.1234
Bottom line from this bounded source set
The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit. The additional urine studies concern detection and receptor binding, not therapeutic benefit.1234
Reviewed study record
Postoperative ileus: a placebo-controlled phase 2 trial
Design
A multicenter blinded randomized placebo-controlled study assessed recovery after bowel resection.1
Population
The trial enrolled 117 adults; 114 were included in its safety and modified intent-to-treat populations.1
Outcomes reported
Time to a tolerated solid meal was not significantly different between groups. Treatment-emergent adverse events occurred in 87.5% with ipamorelin and 94.8% with placebo.1
Limitations
The study was small and included varied underlying conditions. A nonsignificant result does not prove equivalence, and these postoperative findings do not establish safety for other uses or routes.1
Reviewed study record
Healthy-volunteer pharmacokinetics and hormone response
Design
An escalating-exposure study modeled drug concentrations and growth hormone responses.2
Population
The report describes eight healthy men at each of five exposure levels.2
Outcomes reported
The study observed an episode of growth hormone release and substantial between-person variability in pharmacodynamic responses.2
Limitations
The endpoints were pharmacology and hormone measurements, not clinical benefits. The abstract does not provide enough adverse-event detail for a safety conclusion.2
Reviewed study record
Analytical study after nasal exposure
Design
An analytical study examined urine collected over two days after administration of several growth-hormone-releasing peptides.3
Population
The report states that each compound was administered to one volunteer.3
Outcomes reported
The study identified ipamorelin and metabolites in urine using mass spectrometry.3
Limitations
This establishes an analytical human-exposure report, not evidence of therapeutic efficacy or adequately assessed safety. Results for the other compounds cannot be transferred to ipamorelin.3
Reviewed study record
Receptor assay using excretion-study samples
Design
Researchers tested receptor binding of peptides and metabolites and applied the assay to urine from nasal-administration studies.4
Population
The abstract does not state the participant count or establish whether these samples overlap the earlier analytical report.4
Outcomes reported
The assay detected receptor-binding activity in excreted urine from studies that included ipamorelin.4
Limitations
Receptor binding in a sample is not a patient health outcome. Cohort overlap remains unresolved, so this report should not be counted as independent clinical replication.4
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s00384-014-2030-8. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1023/a:1018955126402. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1002/dta.1787. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1002/dta.1947. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The pharmacology study does not establish chronic treatment benefit
FDA’s October 2024 briefing describes intravenous pharmacology in healthy male volunteers. It found no corresponding pharmacokinetic or pharmacodynamic evidence for the proposed subcutaneous route. FDA PDF pp. 35 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
The surgical trial studied a different clinical setting
The safety discussion concerns hospitalized adults after bowel surgery, not a general wellness population or chronic growth-hormone-deficiency treatment. The formulation was not fully specified in the clinical report. FDA PDF pp. 35, 37 ↗
Serious events were reported, with causality unresolved
FDA describes serious postoperative events and two deaths among ipamorelin-treated participants. It explicitly states that their relationship to ipamorelin was unclear, while considering the overall findings a safety concern. FDA PDF pp. 37 ↗
Product quality is part of the uncertainty
FDA raised questions about impurities, aggregates, endotoxins and immunogenicity for the nominated substances. Its staff recommendation against 503A-list inclusion is a pre-decision assessment, not itself a final agency ruling. FDA PDF pp. 1, 40 ↗
What remains to be checked
Check subsequent advisory records and any final FDA action separately from the staff briefing.
Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Original human ipamorelin administration and administration-sample reports, including pharmacokinetics. Reviews, other compounds, preclinical and sample-only method studies are separate evidence categories.
50 retrieved · 4 included · 45 excluded · 1 awaiting a decision · 0 full-text appraisals
Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.
Showing 25 of 50 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 26811125 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety.
PubMed 25869809 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety.
PubMed 25331030 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety. Study families: NCT00672074.
PubMed 10496658 — include: Original human administration or analysis of administration-study samples; analytical exposures do not establish therapeutic benefit or safety. Study families: ipamorelin-1999-pharmacology.
PubMed 26472487 — unresolved: The abstract describes urine containing ipamorelin but does not establish whether the samples followed human administration or were fortified; full text is needed.
PubMed 42578445 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 42395176 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 42160466 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 42123471 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 42021992 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 41966639 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 41880199 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 41490200 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 41476424 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 39043357 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
PubMed 38996787 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
PubMed 32801950 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
PubMed 32257855 — exclude: Review of existing peptide evidence; no new ipamorelin human administration reported.
PubMed 30282322 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
PubMed 30168238 — exclude: Animal, cell or compound-development study, outside the human-administration subset.
PubMed 30136411 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
PubMed 29864719 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
PubMed 27497113 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
PubMed 26578461 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
PubMed 24574167 — exclude: Product/sample-method or nonhuman analytical research; inspected abstracts do not report human ipamorelin administration. Other peptides used in human validation are separate exposures.
ClinicalTrials.gov search
ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.
3 retrieved · 2 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
Other registries and unregistered studies are outside this search.
Showing 3 of 3 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT01280344 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01280344.
ClinicalTrials.gov NCT00672074 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT00672074.
ClinicalTrials.gov NCT07717866 — unresolved: Broad multicomponent protocol lists nonspecific physiological supplementation; ipamorelin exposure is not resolved.
FDA search
Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
products.active_ingredients.name:"IPAMORELIN" OR products.active_ingredients.name:"IPAMORELIN ACETATE"
This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["ipamorelin", "ipamorelin acetate"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["ipamorelin", "ipamorelin acetate"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["ipamorelin", "ipamorelin acetate"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Ipamorelin?
Not FDA-approved; named as an unapproved new drug in a federal enforcement case. FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 exact source-declared trial-publication link connects selected NCT and PMID records. Open the exact graph →
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
A status value is unavailable here for 2 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
1 of 14 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 1
Bibliography fields unavailable here for 13 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
17
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsTrial–publication links · 1
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
We added a plain-language reader guide with cited answers, re-checked FDA’s ipamorelin briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include ipamorelin.
We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available.
The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.
Selected records span November 15, 2012 to May 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained PubMed bibliographic metadata for PMID 39043357 at 2026-07-30T16:20:38.933Z. PubMed recorded a metadata revision date of 2026-05-24 and an Entrez history date of 2024-07-23. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25331030 at 2026-07-30T16:20:34.456Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2014-10-22. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
The Federal Register published notice 2024-21241, attributed to FDA and its parent HHS department, on 2024-09-18. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List; Revisions to the Withdrawn or Removed List,” and PeptideScanner's exact reviewed identity mapping connects the document to Ipamorelin.↗
PubMed lists PMID 38996787 in Animal reproduction science as Journal Article, with publication-date metadata of 2024-07-05 (day precision). PeptideScanner associated the retained record with the identity slug ipamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25869809 at 2026-07-30T20:43:08.964Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2015-04-15. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 9879640 at 2026-07-30T20:46:59.653Z. PubMed recorded a metadata revision date of 2019-09-09 and an Entrez history date of 1999-01-08. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 9849822 at 2026-07-30T20:46:59.652Z. PubMed recorded a metadata revision date of 2019-09-05 and an Entrez history date of 1998-12-16. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 11459660 at 2026-07-30T20:48:24.201Z. PubMed recorded a metadata revision date of 2019-08-19 and an Entrez history date of 2001-07-19. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 10496658 at 2026-07-30T20:48:24.176Z. PubMed recorded a metadata revision date of 2019-08-18 and an Entrez history date of 1999-09-25. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 10828840 at 2026-07-30T20:50:07.370Z. PubMed recorded a metadata revision date of 2019-07-09 and an Entrez history date of 2000-06-01. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 15665799 at 2026-07-30T21:09:05.701Z. PubMed recorded a metadata revision date of 2018-12-17 and an Entrez history date of 2005-01-25. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 9733495 at 2026-07-30T21:08:59.367Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 1998-09-11. PeptideScanner associated this retained record with the identity slug ipamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗